The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Increasing Risk of Relapse after Treatment of Clostridium difficile Colitis in Quebec, Canada
Open accessAbstract
Background.Clinicians who treat patients with Clostridium difficile-associated diarrhea (CDAD) in Quebec, Canada, have noted an apparent increase in the proportion of patients who experience relapse. Methods.To determine whether there was an increase in the frequency of treatment failure and of recurrence of CDAD after treatment, we reviewed data on cases that had been diagnosed in a hospital in the province of Quebec during the period 1991-2004.The frequency of recurrences within 60 days after the initial diagnosis was measured using Kaplan-Meier analysis, and Cox regression was used for multivariate analysis.Results.Among patients who had initially been treated with metronidazole, the proportion whose regimens were switched to vancomycin or for whom vancomycin was added because of a disappointing response did not vary between 1991 and 2002 (66 [9.6%] of 688 patients overall) but more than doubled in 2003-2004 (112 [25.7%] of 435;).Among 845 patients treated with metronidazole only, the 60-day probability of recurrence P !.001increased dramatically in 2003-2004 (47.2%), compared with 1991-2002 (20.8%; ).During 1991-2002, P !.001 the probabilities of recurrence were 20.0%, 13.8%, and 28.9% among individuals aged 0-17, 18-64, and у65 years, respectively; during 2003-2004, the probabilities were 25.0%, 27.1%, and 58.4%, respectively. Conclusion.In 2003-2004, there was an increase in the proportion of patients with CDAD believed, by their attending physicians, to have experienced metronidazole treatment failure, as well as an increase in the frequency of post-metronidazole therapy recurrences, especially among elderly persons.Clostridium difficile was identified as the etiological agent of pseudomembranous colitis in 1978 [1].Early studies claimed that metronidazole was as effective as oral vancomycin for therapy [2,3], and the former became the standard first-line treatment for this common cause of nosocomial infectious diarrhea.After recommendations were made by the Centers for Disease Control and Prevention to avoid the use of vancomycin in the hope of slowing down the emergence of vancomycin-resistant pathogens [4], metronidazole started to be administered to the overwhelming majority of patients with C. difficile-associated diarrhea (CDAD).Unfortunately, 5%-35% of patients experience a recurrence of CDAD, regardless of whether metronida-
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Principles and Practice of Infectious Diseases.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-818_5 · Cited by 12,025
The American Journal of Gastroenterology
(2003) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.80003397.x · Cited by 2,196
Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia
Bartlett, J. G., Chang, T. W., Gurwith, M., Gorbach, S. L., & Onderdonk, A. B. (1978) · New England Journal of Medicine · doi:10.1056/nejm197803092981003 · Cited by 1,374 · cited 1×
“Clostridium difficile was identified as the etiological agent of pseudomembranous colitis in 1978 [1].”
BackgroundAntibiotic-Associated Diarrhea
Bartlett, J. G. (2002) · New England Journal of Medicine · doi:10.1056/nejmcp011603 · Cited by 1,197
Pepin, J. (2004) · Canadian Medical Association Journal · doi:10.1503/cmaj.1041104 · Cited by 1,128
Self-citationAsymptomatic Carriage of Clostridium difficile and Serum Levels of IgG Antibody against Toxin A
Kyne, L., Warny, M., Qamar, A., & Kelly, C. P. (2000) · New England Journal of Medicine · doi:10.1056/nejm200002103420604 · Cited by 935
McFarland, L. V. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510480037031 · Cited by 857
Kyne, L., Warny, M., Qamar, A., & Kelly, C. P. (2001) · The Lancet · doi:10.1016/s0140-6736(00)03592-3 · Cited by 804
Teasley, D., Olson, M., Gebhard, R., Gerding, D., Peterson, L., Schwartz, M., & Lee, J. (1983) · The Lancet · doi:10.1016/s0140-6736(83)91036-x · Cited by 785
(1995) · American Journal of Infection Control · doi:10.1016/0196-6553(95)90104-3 · Cited by 709
Cited by
Cohen, S. H., Gerding, D. N., Johnson, S., Kelly, C. P., Loo, V. G., McDonald, L. C., Pepin, J., & Wilcox, M. H. (2010) · Infection Control & Hospital Epidemiology · doi:10.1086/651706 · Cited by 2,942
Self-citationMcDonald, L. C., Gerding, D. N., Johnson, S., Bakken, J. S., Carroll, K. C., Coffin, S. E., Dubberke, E. R., Garey, K. W., Gould, C. V., Kelly, C., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/cix1085 · Cited by 2,690
Fidaxomicin versus Vancomycin for Clostridium difficile Infection
Louie, T. J., Miller, M. A., Mullane, K. M., Weiss, K., Lentnek, A., Golan, Y., Gorbach, S., Sears, P., & Shue, Y.-K. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0910812 · Cited by 1,585
Warny, M., Pepin, J., Fang, A., Killgore, G., Thompson, A., Brazier, J., Frost, E., & McDonald, L. C. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67420-x · Cited by 1,430
Self-citationClostridium difficile— More Difficult Than Ever
Kelly, C. P., & LaMont, J. T. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707500 · Cited by 1,313
Zar, F. A., Bakkanagari, S. R., Moorthi, K. M. L. S. T., & Davis, M. B. (2007) · Clinical Infectious Diseases · doi:10.1086/519265 · Cited by 1,252
Debast, S. B., Bauer, M. P., & Kuijper, E. J. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12418 · Cited by 1,215
Clostridium difficile infection in Europe: a hospital-based survey
Bauer, M. P., Notermans, D. W., van Benthem, B. H., Brazier, J. S., Wilcox, M. H., Rupnik, M., Monnet, D. L., van Dissel, J. T., & Kuijper, E. J. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61266-4 · Cited by 1,020
Pepin, J., Saheb, N., Coulombe, M.-A., Alary, M.-E., Corriveau, M.-P., Authier, S., Leblanc, M., Rivard, G., Bettez, M., Primeau, V., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/496986 · Cited by 995
Self-citationThe Changing Epidemiology of Clostridium difficile Infections
Freeman, J., Bauer, M. P., Baines, S. D., Corver, J., Fawley, W. N., Goorhuis, B., Kuijper, E. J., & Wilcox, M. H. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00082-09 · Cited by 826
Factors affecting the composition of the gut microbiota, and its modulation
Hasan, N., & Yang, H. (2019) · PeerJ · doi:10.7717/peerj.7502 · Cited by 755
Treatment with Monoclonal Antibodies against Clostridium difficile Toxins
Lowy, I., Molrine, D. C., Leav, B. A., Blair, B. M., Baxter, R., Gerding, D. N., Nichol, G., Thomas, W. D., Leney, M., Sloan, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907635 · Cited by 746
van Prehn, J., Reigadas, E., Vogelzang, E. H., Bouza, E., Hristea, A., Guery, B., Krutova, M., Norén, T., Allerberger, F., Coia, J. E., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.09.038 · Cited by 640
The epidemiology of community-acquired Clostridium difficile infection: a population-based study
Khanna, S., Pardi, D. S., Aronson, S. L., Kammer, P. P., Orenstein, R., St Sauver, J. L., Harmsen, S. W., & Zinsmeister, A. R. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.398 · Cited by 622
Pepin, J. (2005) · Canadian Medical Association Journal · doi:10.1503/cmaj.050978 · Cited by 606
Self-citationNarrative Review: The New Epidemic of Clostridium difficile–Associated Enteric Disease
Bartlett, J. G. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-10-200611210-00008 · Cited by 599
Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis
Janarthanan, S., Ditah, I., Adler, D. G., & Ehrinpreis, M. N. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.179 · Cited by 538
Johnson, S., Louie, T. J., Gerding, D. N., Cornely, O. A., Chasan-Taber, S., Fitts, D., Gelone, S. P., Broom, C., Davidson, D. M., & for the Polymer Alternative for CDI Treatment (PACT) investigators (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu313 · Cited by 527
Antharam, V. C., Li, E. C., Ishmael, A., Sharma, A., Mai, V., Rand, K. H., & Wang, G. P. (2013) · Journal of Clinical Microbiology · doi:10.1128/jcm.00845-13 · Cited by 485
Diagnosis and Treatment of Clostridium difficile in Adults: A Systematic Review
Bagdasarian, N., Rao, K., & Malani, P. N. (2015) · JAMA · doi:10.1001/jama.2014.17103 · Cited by 451
Cammarota, G., Ianiro, G., & Gasbarrini, A. (2014) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000046 · Cited by 428
Systematic Review: Adverse Events of Fecal Microbiota Transplantation
Wang, S., Xu, M., Wang, W., Cao, X., Piao, M., Khan, S., Yan, F., Cao, H., & Wang, B. (2016) · PLOS ONE · doi:10.1371/journal.pone.0161174 · Cited by 409
Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin
Cornely, O. A., Miller, M. A., Louie, T. J., Crook, D. W., & Gorbach, S. L. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis462 · Cited by 401
Recurrent Clostridium difficile infection: A review of risk factors, treatments, and outcomes
Johnson, S. (2009) · Journal of Infection · doi:10.1016/j.jinf.2009.03.010 · Cited by 397
Can we identify patients at high risk of recurrent Clostridium difficile infection?
Kelly, C. P. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12046 · Cited by 396
Mattila, E., Uusitalo–Seppälä, R., Wuorela, M., Lehtola, L., Nurmi, H., Ristikankare, M., Moilanen, V., Salminen, K., Seppälä, M., Mattila, P. S., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.11.037 · Cited by 371
Treatment of Clostridium difficile-associated disease: old therapies and new strategies
Aslam, S., Hamill, R. J., & Musher, D. M. (2005) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(05)70215-2 · Cited by 366
Bauer, M. P., Kuijper, E. J., & van Dissel, J. T. (2009) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2009.03099.x · Cited by 366
Clostridium difficile Infection Caused by the Epidemic BI/NAP1/027 Strain
O'Connor, J. R., Johnson, S., & Gerding, D. N. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.02.073 · Cited by 357
Clostridium difficile infection: epidemiology, risk factors and management
Ananthakrishnan, A. N. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.190 · Cited by 352
Valiquette, L., Cossette, B., Garant, M.-P., Diab, H., & Pépin, J. (2007) · Clinical Infectious Diseases · doi:10.1086/519258 · Cited by 330
Self-citationAbou Chakra, C. N., Pepin, J., Sirard, S., & Valiquette, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098400 · Cited by 328
Self-citationJohnson, S., Schriever, C., Galang, M., Kelly, C. P., & Gerding, D. N. (2007) · Clinical Infectious Diseases · doi:10.1086/511870 · Cited by 312
Enteropathogenic Bacteria in Dogs and Cats: Diagnosis, Epidemiology, Treatment, and Control
Marks, S. L., Rankin, S. C., Byrne, B. A., & Weese, J. S. (2011) · Journal of Veterinary Internal Medicine · doi:10.1111/j.1939-1676.2011.00821.x · Cited by 305
Barbut, F., Mastrantonio, P., Delmée, M., Brazier, J., Kuijper, E., & Poxton, I. (2007) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2007.01824.x · Cited by 297
Abt, M. C., Lewis, B. B., Caballero, S., Xiong, H., Carter, R. A., Sušac, B., Ling, L., Leiner, I., & Pamer, E. G. (2015) · Cell Host & Microbe · doi:10.1016/j.chom.2015.06.011 · Cited by 294
Treatment of Clostridium difficile Infection
Gerding, D. N., Muto, C. A., & Owens, Jr. (2008) · Clinical Infectious Diseases · doi:10.1086/521860 · Cited by 287
Diversity and Evolution in the Genome of Clostridium difficile
Knight, D. R., Elliott, B., Chang, B. J., Perkins, T. T., & Riley, T. V. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00127-14 · Cited by 286
Crook, D. W., Walker, A. S., Kean, Y., Weiss, K., Cornely, O. A., Miller, M. A., Esposito, R., Louie, T. J., Stoesser, N. E., Young, B. C., et al. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis499 · Cited by 260
Clostridium difficile and inflammatory bowel disease
Issa, M., Ananthakrishnan, A. N., & Binion, D. G. (2008) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20500 · Cited by 257
Clostridium difficile in Retail Ground Meat, Canada
Rodriguez-Palacios, A., Staempfli, H. R., Duffield, T., & Weese, J. S. (2007) · Emerging Infectious Diseases · doi:10.3201/eid1303.060988 · Cited by 254
Recent advances in the understanding of antibiotic resistance in Clostridium difficile infection
Spigaglia, P. (2016) · Therapeutic Advances in Infectious Disease · doi:10.1177/2049936115622891 · Cited by 254
Gut Dysbiosis in Patients with Anorexia Nervosa
Morita, C., Tsuji, H., Hata, T., Gondo, M., Takakura, S., Kawai, K., Yoshihara, K., Ogata, K., Nomoto, K., Miyazaki, K., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0145274 · Cited by 238
Models for the study of Clostridium difficile infection
Best, E. L., Freeman, J., & Wilcox, M. H. (2012) · Gut Microbes · doi:10.4161/gmic.19526 · Cited by 135
Russell, G., Kaplan, J., Ferraro, M., & Michelow, I. C. (2010) · PEDIATRICS · doi:10.1542/peds.2009-3363 · Cited by 120
A Canadian Working Group report on fecal microbial therapy: microbial ecosystems therapeutics
Allen-Vercoe, E., Reid, G., Viner, N., Gloor, G. B., Hota, S., Kim, P., Lee, C., O’Doherty, K. C., Vanner, S. J., Weese, J. S., et al. (2012) · Canadian Journal of Gastroenterology · doi:10.1155/2012/213828 · Cited by 81
Clinical Guideline for the Diagnosis and Treatment of Gastrointestinal Infections
The Korean Society of Infectious Diseases, Korean Society for Chemotherapy, & The Korean Society of Clinical Microbiology (2010) · Infection and Chemotherapy · doi:10.3947/ic.2010.42.6.323 · Cited by 18
Metadata
- Authors
- Pepin, J., Alary, M.-E., Valiquette, L., Raiche, E., Ruel, J., Fulop, K., Godin, D., & Bourassa, C.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-06-01
- Volume
- 40
- Issue
- 11
- Pages
- 1591-1597
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2163918813
- Cited by
- 570
- References
- 26
- FWCI
- 27.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.